替吉奥与吉西他滨一线治疗老年晚期胰腺癌对比研究

Comparative Study of Tegafur and Gemcitabine in the Treatment of Elderly Advanced Pancreatic Cancer

目的探究替吉奥与吉西他滨一线治疗老年晚期胰腺癌的临床疗效。方法回顾性分析我院收治的48例老年晚期胰腺癌患者,对照组24例予以吉西他滨单药治疗,研究组24例予以替吉奥单药治疗。统计两组患者临床效果及不良反应发生率。结果研究组骨髓抑制副反应发生率低于对照组,其中Ⅲ~Ⅳ级中性粒细胞减少发生率低于对照组,差异有统计学意义（P〈0.05）。结论替吉奥治疗老年晚期胰腺癌,保障治疗效果同时,还可降低其化疗不良反应发生率,在临床治疗中具有重要意义。

Objective To explore clinical efficacy of tegafur versus gemcitabine alone on elderly patients with advanced pancreatic cancer. Methods The clinical data of 48 elderly patients with advanced pancreatic cancer treated in our hospital were retrospectively analyzed, the control group of 24 cases received gemcitabine treatment, study group of 24 cases received tegafur treatment. The clinical effect and adverse reaction rate of the two groups were statistically analyzed. Results In the study group, the bone marrow suppression side effect was lower than that of the control group, the incidence rate of Ⅲ ~ Ⅳ was much lower than that of the control group, the difference was statistically significant（P〈0.05）. Conclusion Tegafur in treatment of elderly patients with advanced pancreatic cancer,ensure the treatment effect, at the same time, it can reduce the incidence of adverse drug reactions, and it is of great significance in clinical treatment.